enmetazobactam   Click here for help

GtoPdb Ligand ID: 12188

Synonyms: AAI101 | Exblifep® (cefepime + enmetazobactam) | OCID-5090
Approved drug
enmetazobactam is an approved drug (FDA & EMA (2024))
Compound class: Synthetic organic
Comment: Enmetazobactam is an extended-spectrum β-lactamase inhibitor. It is an N-methylated tazobactam derivative. It is intended for use alongside β-lactamase antimicrobials, to reduce their degradation.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 0
Rotatable bonds 3
Topological polar surface area 124.66
Molecular weight 314.07
XLogP -1.75
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES [O-]C(=O)[C@@H]1N2C(=O)C[C@H]2S(=O)(=O)[C@@]1(C)Cn1cc[n+](n1)C
Isomeric SMILES C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)[O-])Cn1cc[n+](n1)C
InChI InChI=1S/C11H14N4O5S/c1-11(6-14-4-3-13(2)12-14)9(10(17)18)15-7(16)5-8(15)21(11,19)20/h3-4,8-9H,5-6H2,1-2H3/t8-,9+,11+/m1/s1
InChI Key HFZITXBUTWITPT-YWVKMMECSA-N
No information available.
Summary of Clinical Use Click here for help
Cefepime + enmetazobactam was evaluated for efficacy in the treatment of complicated urinary tract infections [1]. The combination (Exblifep®) was FDA approved for this indication in February 2024 and by the EMA the following month.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03687255 Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections Phase 3 Interventional Allecra 2